Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

Autor: Leyre Pérez-Ricarte, Marta Benavent, A. Viudez, Maria Del Carmen Riesco, Paula Jiménez-Fonseca, Juan Jesús Marín-Méndez, Iranzu González-Borja, Marta Llanos, Saioa Goñi, Jaume Capdevila, Beatriz García-Paredes, Vicente Alonso, Ana Custodio, Maika Durantez, J. Hernando, Rocio Garcia-Carbonero, Imanol Arozarena, Isabel Sevilla, Ana De Jesus Acosta, Irene Hernández-García, Guillermo Crespo, Alberto Carmona-Bayonas, Jairo Pérez-Sanz, Maria Luisa Gomez Dorronsoro, Ruth Vera, Borja Lopez De San Vicente, Carlos F. Lopez
Rok vydání: 2021
Předmět:
Adult
Male
Oncology
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
Cell Cycle Proteins
Neuroendocrine tumors
Capecitabine
Young Adult
03 medical and health sciences
0302 clinical medicine
Cell Line
Tumor
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
medicine
Humans
In patient
Everolimus
DNA Modification Methylases
Domain family
Aged
Aged
80 and over
Temozolomide
Hepatology
business.industry
Tumor Suppressor Proteins
Intracellular Signaling Peptides and Proteins
Gastroenterology
Nuclear Proteins
Middle Aged
Prognosis
medicine.disease
Immunohistochemistry
Survival Analysis
Progression-Free Survival
Pancreatic Neoplasms
Neuroendocrine Tumors
DNA Repair Enzymes
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
030211 gastroenterology & hepatology
Neoplasm Recurrence
Local
business
Immunosuppressive Agents
medicine.drug
Zdroj: Pancreatology. 21:215-223
ISSN: 1424-3903
Popis: Background Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival. Methods In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed. Results In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus. Conclusion From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
Databáze: OpenAIRE
Externí odkaz: